Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Abbott Laboratories (ABT) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott Laboratories (ABT) - free report >>
Image: Bigstock
Shire (SHPG) Gets EU Nod for Label Expansion of Revestive
Shire plc announced that the European Commission has granted an extension of the market authorization for its gastrointestinal drug (GI) Revestive for use in the pediatric population.
Revestive 5 mg powder and solvent has been approved for the treatment of patients aged one year and above with short bowel syndrome (SBS).
An approval was on the cards given that the Committee for Medicinal Products for Human Use (CHMP) had given a positive opinion on the same in May 2016.
We remind investors that Revestive is approved in Europe for the treatment of adult patients with SBS who have become stable following a period of intestinal adaptation post surgery. The drug is also approved in the U.S. as Gattex for injection in adult patients with SBS who are dependent on parenteral support.
The label expansion of Revestive for use in the pediatric population should boost its sales.
We note that Shire has a solid presence in the rare disease markets. The company acquired NPS Pharmaceuticals Inc. in Feb 2015, thereby adding Revestive/Gattex and Natpara (hypoparathyroidism) to its portfolio and providing a major boost to its GI franchise.
SHIRE PLC-ADR Price
SHIRE PLC-ADR Price | SHIRE PLC-ADR Quote
We are also encouraged by the company’s efforts to develop its GI franchise. Last month, the company acquired global rights to Pfizer Inc.'s (PFE - Free Report) PF-00547659 for the treatment of moderate-to-severe inflammatory bowel disease (IBD). Shire also obtained Breakthrough Therapy Designation from the FDA for two of its GI candidates – SHP621 (budesonide oral suspension, or BOS) for eosinophilic esophagitis (EoE), and SHP625 (maralixibat) for progressive familial intrahepatic cholestasis type 2 (PFIC2).
Shire currently has a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the healthcare sector include Abbott Laboratories (ABT - Free Report) and Johnson & Johnson (JNJ - Free Report) . Both stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>